Company Overview Alitair is a specialty pharmaceutical company focused on developing proprietary ion-exchange resin formulations, prescription cough medicines, and a pipeline of Orphan Drugs. Our proprietary formulation technology and portfolio of respiratory products address unmet medical needs. Our portfolio consists of patent protected, late-stage, well-characterized small molecules with clear regulatory paths to approval. Pipeline We have a robust pipeline of non-narcotic respiratory drug, ion exchange resin formulations, and orphan drugs. Our patented Overdose Reduction formulation (ODR) acts as a passive drug formulation system to reduce the risk of prescription drug overdose no matter how many tablets or capsules are ingested. Corporate Businesses Development Strategy Our businesses development strategy is comprised of three key goals: (1) internal product development; (2) out-licensing opportunities, especially related to our Overdose Reduction™ (ODR) ion-exchange technology; and (3) strategic alliances or partnerships related to our products and therapeutic areas. As we expand our global pharmaceuticals business, Alitair is committed to identifying opportunities that fit our capabilities, enhance our corporate goals, and strengthen our competitive position while also strengthening our partner’s position. Visit our website to learn more about our company, pipeline, and business development strategies.